117 related articles for article (PubMed ID: 22800904)
1. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials.
Song HF; Wang S; Li HW
Chin Med J (Engl); 2012 May; 125(10):1804-10. PubMed ID: 22800904
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients.
Geng DF; Jin DM; Wu W; Xu Y; Wang JF
Int J Cardiol; 2012 Mar; 155(2):236-42. PubMed ID: 21036409
[TBL] [Abstract][Full Text] [Related]
3. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
Kuti EL; Baker WL; White CM
Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
5. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
6. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.
Gillespie EL; White CM; Kardas M; Lindberg M; Coleman CI
Diabetes Care; 2005 Sep; 28(9):2261-6. PubMed ID: 16123505
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
Abuissa H; Jones PG; Marso SP; O'Keefe JH
J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
10. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
11. [Antihypertensive therapy and cardiovascular prevention. The role of angiotensin II receptor blockers].
Verdecchia P; Cavallini C; Angeli F; Andreani F; Garofoli M; Reboldi GP; Ambrosio G
G Ital Cardiol (Rome); 2007 Aug; 8(8):491-7. PubMed ID: 17695700
[TBL] [Abstract][Full Text] [Related]
12. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
Zaiken K; Hudd TR; Cheng JW
Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
[TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
McCall KL; Craddock D; Edwards K
Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
[TBL] [Abstract][Full Text] [Related]
16. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials.
Hopper I; Billah B; Skiba M; Krum H
Eur J Cardiovasc Prev Rehabil; 2011 Dec; 18(6):813-23. PubMed ID: 21878448
[TBL] [Abstract][Full Text] [Related]
17. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin-system blockade in the prevention of diabetes.
Ostergren J
Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension.
Cheung BM; Cheung GT; Lauder IJ; Lau CP; Kumana CR
J Hum Hypertens; 2006 Jan; 20(1):37-43. PubMed ID: 16121197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
